logo
logo

Sherlock Biosciences Raises $80 Million In Series B Financing To Democratize At-Home Diagnostic Testing

Mar 08, 2022•over 3 years ago

Amount Raised

$80 Million

Round Type

series b

Boston

Description

Sherlock Biosciences, a company engineering biology to bring next-generation diagnostics to the point-of-need, today announced it has raised $80 million in a Series B financing. The round was led by Novalis LifeSciences and included new investors Illumina Ventures, Albany Capital and Catalio Capital Management, among others. They joined Northpond Ventures, Good Ventures, and other existing investors, bringing $111 million in total funding raised to date.

Company Information

Company

Sherlock Biosciences

Location

Boston, Massachusetts, United States

About

Sherlock Biosciences is developing products that will empower people to access answers and have more control over their health decisions. Through our engineering biology tools, CRISPR-based SHERLOCKTM and synthetic biology-based INSPECTRTM, we are bringing together the accuracy of PCR with the convenience and simplicity of antigen tests for molecular diagnostics at the point-of-need. SHERLOCK and INSPECTR can be used in virtually any setting without complex instrumentation, making it well suited for use in the home and in low resource settings, opening up a wide range of potential applications in areas including infectious disease, early detection of cancer, treatment monitoring, and precision medicine. In 2020 the company made history with the first FDA-authorized use of CRISPR technology. For more information please visit www.sherlock.bio.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech